Первая клетка. И чего стоит борьба с раком до последнего

Johnson J. Intelligent Toilets, Smart Couches and the House of the Future. Financial Post, June 6, 2012. http://business.financialpost.com/uncategorized/

intelligent-toilets-smart-couches-and-the-house-of-the-future

Wang L. Microwave Sensors for Breast Cancer Detection. Sensors. 18, no. 2 (2018): 655.

Hsu J. Can a New Smart Bra Really Detect Cancer? Live Science, October 17, 2012.

Kahn N. et al. Dynamic Nanoparticle-Based Flexible Sensors: Diagnosis of Ovarian Carcinoma from Exhaled Breath. Nano Letters. 15, no. 10 (2015): 7023–7028.

Czernin J., Gambhir S. S. Discussions with Leaders: A Conversation Between Sam Gambhir and Johannes Czernin

. Journal of Nuclear Medicine. 59, no. 12 (2018): 1783–1785.

Vermesh O. et al. An Intravascular Magnetic Wire for the High-Throughput Retrieval of Circulating Tumour Cells In Vivo. Nature Biomedical Engineering. 2, no. 9 (2018): 696–705.

Ferrari E. et al. Urinary Proteomics Profiles Are Useful for Detection of Cancer Biomarkers and Changes Induced by Therapeutic Procedures. Molecules. 24, no. 4 (2019): 794.

Colditz G. A. et al. Applying What We Know to Accelerate Cancer Prevention. Science Translational Medicine. 4, no. 127 (2012): 127rv4.

Wan J. C. et al. Liquid Biopsies Come of Age: Towards Implementation of Circulating Tumour DNA. Nature Reviews Cancer. 17 (2017): 223–238.

Bianchi D. W. Circulating Fetal DNA: Its Origin and Diagnostic Potential – A Review. Placenta. 25, supplement (2004): S93–S101.

Jahr S. et al. DNA Fragments in the Blood Plasma of Cancer Patients: Quantitations and Evidence for Their Origin from Apoptotic and Necrotic Cells. Cancer Research. 61 (2001): 1659–1665.

Thierry A. R. et al. Clinical Validation of the Detection of KRAS and BRAF Mutations from Circulating Tumor DNA. Nature Medicine. 20 (2014): 430–435.

Ding L. et al. Expanding the Computational Toolbox for Mining Cancer Genomes. Nature Reviews Genetics. 15, no. 8 (2014): 556–570.

Murtaza M. et al. Non-Invasive Analysis of Acquired Resistance to Cancer Therapy by Sequencing of Plasma DNA

. Nature. 497 (2013): 108–112.

Siravegna G. et al. Integrating Liquid Biopsies into the Management of Cancer. Nature Reviews Clinical Oncology. 14 (2017): 531–548.

Taylor D. D., Gercel-Taylor C. MicroRNA Signatures of Tumor-Derived Exosomes as Diagnostic Biomarkers of Ovarian Cancer. Gynecologic Oncology. 110 (2008): 13–21.

Yuan Z. Dynamic Plasma MicroRNAs Are Biomarkers for Prognosis and Early Detection of Recurrence in Colorectal Cancer. British Journal of Cancer. 117 (2017): 1202–1210.

Hinkson I., IV et al. A Comprehensive Infrastructure for Big Data in Cancer Research: Accelerating Cancer Research and Precision Medicine. Frontiers in Cell and Developmental Biology, September 21, 2017. doi:10.3389/fcell.2017.00083.

Philippidis A. Next-Gen Diagnostics: Thermo Fisher Scientific, University Hospital Basel Partner to Develop, Validate NGS Cancer Diagnostics. Clinical OMICs. 4, no. 3 (2017). doi:10.1089/clinomi.04.03.17.

BloodPac: Blood Profiling Atlas in Cancer. www.bloodpac.org